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AbstrAct
Objectives The impact of inhaled corticosteroids 
(ICS) on eosinophilic inflammation in asthma is well 
established, but their effect in a real-life setting has not 
been extensively studied. Our purpose was to investigate 
the effect of ICS on airway and systemic inflammation as 
well as on clinical outcomes in patients with asthma from 
clinical practice.
Design, setting and participants We conducted a 
retrospective analysis on asthmatics from a secondary 
care centre in whom ICS were initiated/increased (n=101), 
stopped/decreased (n=60) or remained stable (n=63, 
used as a control group) between two visits with available 
sputum and blood cell counts.
results The median time between both visits ranged 
from 1 to 2 years. Initiating or increasing ICS (median 
variation (IQR): 800 (400–1200) µg beclomethasone 
equivalent dose per day) reduced sputum eosinophils and 
fractional exhaled nitric oxide (P<0.0001) and to a lesser 
extent blood eosinophils (P<0.0001), while withdrawing or 
decreasing ICS (median variation (IQR): 900 (500–1200) µg 
beclomethasone equivalentdose per day) resulted in 
increased sputum eosinophils (P=0.008). No change was 
found in patients with a stable dose. The effectiveness 
of ICS in improving asthma control, quality of life, 
forced expiratory volume in 1 s (FEV
1), bronchial hyper-
responsiveness and exacerbation rate was only observed 
in the eosinophilic phenotype (sputum eosinophils ≥3%, 
n=79). In non-eosinophilic asthmatics, stepping-down ICS 
resulted in an improvement in asthma control and quality 
of life, without any significant change in FEV
1 (n=38).
conclusions Our results confirm the effectiveness of ICS 
on eosinophilic inflammation in real life and demonstrate 
that their clinical benefit seems to be restricted to 
eosinophilic asthmatics. Our data also support a try for 
stepping-down ICS in non-eosinophilic asthmatics.
IntrODuctIOn
Inhaled corticosteroids (ICS) are considered 
as the mainstay of asthma treatment. They 
have proved their ability to improve asthma 
control, quality of life, lung function and to 
reduce the rate of exacerbations in patients 
with asthma.1 Their effects are thought to be 
mediated by controlling airway inflammation 
and in particular by reducing the eosinophilic 
airway infiltration.2 Previous studies showed 
that an initiation of ICS reduced sputum 
eosinophils,3–7 while the reverse was observed 
with a withdrawal8 or a decrease of ICS.9 The 
effect of ICS on other sputum cell types, 
however, is more controversial.3 4 6 7 Like-
wise, whether ICS impact circulating leuco-
cytes has been much less studied. Very few 
studies reported that ICS decreased blood 
eosinophils6 7 10 11 with no change in blood 
neutrophils,10 but their effect on other blood 
leucocytes still needs to be determined.
It is now recognised that asthma exhibits 
different airway inflammatory phenotypes.12 
Pavord et al first showed that the initiation 
of budesonide 800 µg/day for 2 months 
improved asthma symptoms and reduced 
bronchial hyper-responsiveness to methacho-
line in patients with sputum eosinophils ≥3%, 
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Research
strengths and limitations of this study
 ► Our study population consisted of patients from real 
life.
 ► We included a control group with patients not 
receiving inhaled corticosteroids (ICS) or keeping 
the same dose of ICS between two visits, in order 
to properly investigate the effects of an initiation/
increased dose and cessation/decreased dose of 
ICS between two visits.
 ► Our study was retrospective.
 ► No formal sample size calculation was performed.
 ► The cumulative dose of ICS received by the patients 
before the investigation was uncertain due to the 
variation in the delay between both visits and to the 
unknown adherence to treatment.
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whereas no effect was observed in those with sputum 
eosinophils <3%.13 Other studies, with one of them based 
on a randomised, double-blind, placebo-controlled cross-
over design,14 confirmed the importance of sputum 
eosinophils as a predictive marker of response to ICS,4 10 
even if some authors reported a possible effect in non-eo-
sinophilic asthmatics.15 16 Moreover, some studies with a 
limited number of subjects have shown that patients expe-
riencing loss of asthma control after stepping-down ICS 
treatment were more likely to have eosinophilic asthma, 
while patients in whom this strategy might be acceptable 
were more often non-eosinophilic.9 17
We believe that it is important to validate findings 
from tightly regulated clinical trials in a real-life setting 
including a broad spectrum of patients with asthma who 
may not qualify for inclusion criteria in these trials.18 
In this study, we took advantage of our large database 
of asthmatics seen in clinical practice to investigate the 
effect of ICS in real life on airway and systemic inflam-
mation as well as on asthma control and lung function. 
We have selected 224 patients in whom ICS dose was initi-
ated/increased (n=101), stopped/decreased (n=60) or 
remained stable (n=63) between two visits and in whom 
we had an analysed sputum and blood cell count for both 
these visits.
MethODs
study design, setting and participants
We conducted a retrospective study on patients with 
asthma recruited from the University Asthma Clinic of 
Liege (Belgium) between 1 May 2003 and 31 January 
2017. The diagnosis of asthma was defined as the presence 
of typical symptoms (wheezing, breathlessness, chest tight-
ness and cough) associated with the demonstration of an 
airflow variability (increase in forced expiratory volume 
in 1 s (FEV1) of at least 12% and 200 mL after inhalation 
of 400 µg salbutamol and/or a provocative concentration 
of methacholine causing a 20% fall in FEV1 (PC20M) 
<16 mg/mL. From our database, we selected patients who 
had at least two visits with a successful sputum and blood 
cell count and who were not treated with oral corticoste-
roids (OCS) at the time of the visit or during the 6 previous 
weeks. Those who were prescribed OCS during the visit 
because of an exacerbation were also excluded, as well as 
those treated with omalizumab and mepolizumab because 
these drugs may have confounding effects on sputum and 
blood cell counts. Three groups of patients were consti-
tuted: a first group of patients with an initiation/increased 
dose of ICS between two visits (n=101), a second group of 
patients with a cessation/decreased dose of ICS between 
two visits (n=60) and a third group of patients, used as a 
control group, with no ICS or a stable dose of ICS between 
two visits (n=63). For each patient, the delay between both 
visits was at least of 1 month.
Investigations conducted at the Asthma clinic
Patients were classified as atopic if they had positive 
specific IgE (>0.35 kU/L) to at least one of the following 
aeroallergens: cat, dog, grass pollen, tree pollen, house 
dust mite and a mould mixture (Phadia, Groot-Bijgaarden, 
Belgium). Asthma control and quality of life were eval-
uated by the Juniper Asthma Control Questionnaire 
(ACQ)19 and mini-Asthma Quality of Life Questionnaire 
(mini-AQLQ),20 respectively. When patients’ visits were 
separated by at least 1 year, the number of severe exacer-
bations during the year prior to each visit was recorded. 
Severe exacerbations were defined as events requiring 
the use of systemic corticosteroids during at least 3 days.21 
Spirometry was performed using a portable spirometer 
(Spirobank; MIR, Rome, Italy) connected to the computer 
software (Winspiro; MIR, Rome, Italy). Patients who had 
a FEV1 ≥70% predicted without any influence of bron-
chodilators underwent a methacholine challenge test to 
define the PC20M, as previously described.22 Fractional 
exhaled nitric oxide (FENO) was measured at a flow rate 
of 50 mL/s (NIOX; Aerocrine, Solna, Sweden). Sputum 
was induced and processed as previously described,23 with 
the whole expectorate technique. Patients were classified 
as eosinophilic or non-eosinophilic if they had a baseline 
sputum eosinophil count ≥ or <3%, respectively.24 The 
blood cell count and analysis of C reactive protein (CRP) 
and fibrinogen were performed by the routine laboratory 
of the University Hospital of Liege.
statistical analysis
For categorical variables, the number of observations 
and percentage for each category were presented. For 
continuous variables compatible with a normal distri-
bution, the mean and SD were used, while the median 
and IQR were preferred for continuous variables not 
compatible with a normal distribution. Comparisons 
between the three groups of patients were performed 
using a Pearson’s χ2 test for categorical variables, an 
analysis of variance for parametric continuous variables 
and a Kruskal-Wallis test for non-parametric continuous 
variables. Paired comparisons were performed between 
both visits of patients. The McNemar test was used to 
compare binary variables, the paired t test was used for 
continuous variables when the differences between both 
visits were compatible with a normal distribution and 
the Wilcoxon signed-rank test was preferred for contin-
uous variables when the differences between both visits 
were not compatible with a normal distribution. For 
each tested variable, when the number of missing values 
exceeded 10%, the number of data taken into account 
in the statistical analysis was specified in the tables. For 
the group with an initiation/increased dose of ICS and 
the group with a cessation/decreased dose of ICS, we 
compared the changes in ACQ, mini-AQLQ, severe 
exacerbation rate and FEV1 between eosinophilic and 
non-eosinophilic asthmatics, using a Student’s t-test or 
a Mann-Whitney test. A P value <0.05 was considered 
statistically significant. We used STATA V.13.0 (Statistical 
Software, StataCorp LP) for the statistical analysis and 
GraphPad Prism V.7.03 (GraphPad Software, La Jolla, 
California, USA) for the figures.
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Table 1 Subjects’ characteristics
Patients with an 
initiation/increased dose 
of ICS between two 
visits
Patients with a 
cessation/decreased 
dose of ICS between two 
visits
Patients with no ICS 
or a stable dose of 
ICS between two 
visits P value
n 101 60 63 –
Time between the two visits, years 1.0 (0.5–2.6) 1.5 (0.9–2.6) 2.0 (0.7–3.8) 0.045
Women, n (%) 56 (55) 33 (55) 41 (65) 0.41
Age, years 53 (40–63) 51 (37–62) 53 (44–66) 0.42
BMI, kg/m² 26.3±5.1 26.4±4.7 26.8±4.9 0.83
Atopy, n (%) 52 (51) 35 (58) 32 (51) 0.64
Age of asthma onset, years 41 (16–57) 31 (8–53) 46 (27–55) 0.12
Smoking status, n (%) 0.22
  Non-smokers 53 (52) 31 (52) 32 (51)
  Current smokers 11 (11) 11 (18) 15 (24)
  Ex-smokers 37 (37) 18 (30) 16 (25)
Patients with EA at first visit, n (%) 79 (78) 22 (37) 26 (41) <0.001
Variation of ICS dose* 800 (400–1200) 900 (500–1200) 0 –
*ICS dose expressed in beclomethasone chlorofluorocarbon (CFC) equivalents.
BMI, body mass index; EA, eosinophilic asthma; ICS, inhaled corticosteroid.
results
subjects’ characteristics
Demographic characteristics of patients are given in 
table 1. The three groups were well matched regarding 
sex, age, body mass index, atopy, age of asthma onset 
and smoking status. The median time between two visits 
ranged from 1 to 2 years. The median increase in the ICS 
dose was 800 µg beclomethasone equivalent dose per day, 
while the median decrease was 900 µg beclomethasone 
equivalent dose per day.
effect of an initiation/increased dose of Ics between two 
visits
The effects of an initiation (n=44)/increased dose 
(n=57) of ICS between two visits in the whole cohort are 
shown in table 2. There was a significant improvement 
in asthma control, asthma quality of life and airway 
hyper-responsiveness to methacholine by more than 
one doubling dilution. Initiating or increasing the dose 
of ICS led to a highly significant decrease of 57% in 
FENO and 80% in absolute sputum eosinophils. There 
was also a slight but significant reduction in absolute 
blood eosinophils (19%), lymphocytes (8%) and baso-
phils (12%).
effect of a cessation/decreased dose of Ics between two 
visits
In the whole cohort (table 3), withdrawing (n=18) 
or decreasing (n=42) the dose of ICS led to a signifi-
cant selective threefold increase in absolute sputum 
eosinophils and a slight decrease in absolute blood 
neutrophils (13%).
Analysis in patients with no Ics or the same dose of Ics 
between two visits
In patients with no ICS (n=20) or the same dose of ICS 
(n=43) between two visits (table 4), there was no statisti-
cally significant change in clinical outcomes and absolute 
sputum and blood cells over time.
effect of an initiation/increased dose of Ics between two 
visits according to the baseline eosinophilic phenotype
After initiating (n=35) or increasing (n=44) ICS, eosin-
ophilic asthmatics showed a significant improvement in 
asthma control, quality of life and FEV1 together with a 
reduction of bronchial hyper-responsiveness and severe 
exacerbations (table 5). A higher use of long-acting β2 
agonists (LABA) was also concomitant with the initia-
tion/increase of ICS. As for the sputum and blood cells, 
there was a decreased number of sputum eosinophils, 
blood eosinophils and blood lymphocytes (table 5). 
When excluding patients with an initiation of LABA 
from the analysis, there was still a statistically significant 
improvement (P<0.05) in ACQ (2.6±1.2 to 2.2±1.3), mini-
AQLQ (4.0±1.4 to 4.3±1.5), severe exacerbation number 
(0.7±0.3 to 0.1±0.1), PC20M (1.03 (0.30–3.82) to 3.11 
(1.14–8.25) mg/mL), FENO (60 (24–95) to 24 (14–52) 
parts per billion), sputum eosinophils (282 (82–992) 
to 113 (15–474) × 103/g and 27.0 (8.0–43.4) to 6.3 
(1.3–20.4)%) and blood eosinophils (354 (217–659) to 
293 (141–459))/µL). In this subgroup, there was also a 
marginal significance for an increase in FEV1 (76.6±18.7 to 
79.7%±21.5% predicted, P=0.10) and a decrease in blood 
lymphocytes (2462 (2119–2949) to 2287 (1779–2948)/µL, 
P=0.058).
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Table 2 Comparison of clinical, treatment, sputum and blood characteristics before and after an initiation/increased dose of 
ICS
Patients before an initiation/
increased dose of ICS
(N=101)
Patients after an initiation/
increased dose of ICS
(N=101) P value
ACQ 2.1±1.2 1.7±1.3 0.003
Mini-AQLQ 4.6±1.4 4.9±1.5 0.0008
Number of severe exacerbations in the previous 
year*
0.6±0.2† 0.2±0.1† 0.10
Prebronchodilator FEV1, % predicted 79.1±18.9 81.7±19.8 0.08
PC20M, mg/mL 1.58 (0.30–3.82)‡ 3.42 (0.93–>16)‡ 0.001
ICS dose, beclomethasone equivalents 400 (0–800) 1000 (800–2000) –
LABA, n (%) 51 (51) 91 (90) <0.0001
LTRA, n (%) 21 (21) 24 (24) 0.65
Theophylline, n (%) 3 (3) 3 (3) 1.0
Antihistamine, n (%) 18 (18) 19 (19) 1.0
FENO, ppb 60 (24–98)§ 26 (16–52)§ <0.0001
Sputum total non-squamous cell count, × 106/g 1.48 (0.66–3.56) 1.46 (0.72–3.09) 0.81
Sputum viability, % 72 (54–84) 68 (55–82) 0.67
Sputum squamous cells, % 13 (5–24) 14 (5–28) 0.22
Sputum eosinophils
  × 103/g 221 (43–696) 45 (7–266) <0.0001
  % of non-squamous cells 13.2 (3.8–36.0) 3.8 (0.4–15.4) <0.0001
Sputum neutrophils
  × 103/g 460 (171–1352) 744 (286–1697) 0.13
  % of non-squamous cells 38.6 (20.2–64.4) 59.8 (37.6–79.4) <0.0001
Sputum macrophages
  × 103/g 302 (99–957) 253 (98–642) 0.40
  % of non-squamous cells 22.8 (9.6–34.8) 18.8 (8.8–31.8) 0.22
Sputum lymphocytes
  × 103/g 21 (2–52) 13 (2–39) 0.21
  % of non-squamous cells 1.2 (0.4–2.4) 1.2 (0.2–2.5) 0.83
Sputum epithelial cells
  × 103/g 41 (14–152) 37 (8–119) 0.73
  % of non-squamous cells 3.4 (1.4–6.8) 2.6 (1.0–7.6) 0.57
Blood leucocytes, × 109/L 7.66 (6.47–8.77) 7.59 (6.47–9.04) 0.37
Blood eosinophils
  /µL 272 (185–509) 221 (122–413) <0.0001
  % 3.8 (2.3–5.7) 2.9 (1.6–5.6) <0.0001
Blood neutrophils
  /µL 3976 (3201–4895) 4098 (3466–5344) 0.25
  % 53.4 (46.6–58.8) 54.8 (50.4–62.4) 0.0007
Blood monocytes
  /µL 513 (385–668) 559 (414–692) 0.22
  % 6.5 (5.3–8.2) 7.1 (5.7–8.6) 0.046
Blood lymphocytes
  /µL 2527(2083–2926) 2329 (1771–2900) 0.021
  % 33.2 (26.6–38.0) 31.3 (26.1–36.9) 0.061
Continued
 o
n
 16 August 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-018186 on 28 November 2017. Downloaded from 
 5Demarche SF, et al. BMJ Open 2017;7:e018186. doi:10.1136/bmjopen-2017-018186
Open Access
Patients before an initiation/
increased dose of ICS
(N=101)
Patients after an initiation/
increased dose of ICS
(N=101) P value
Blood basophils
  /µL 43 (25–63) 38 (22–50) 0.016
  % 0.5 (0.4–0.7) 0.4 (0.3–0.6) 0.026
CRP, mg/L 1.9 (0.7–3.9)¶ 1.5 (0.8–4.3)¶ 0.66
Fibrinogen, g/L 3.3 (2.8–3.7)** 3.3 (2.8–3.6)** 0.83
*Data are presented as mean±SEM.
Data available for both visits in: †35, ‡27, §91, ¶69 and **64 patients.
ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; CRP, C reactive protein; FENO, fractional 
exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid; LABA, long-acting β2 agonist; LTRA, 
leukotriene receptor antagonist; PC20M, provocative concentration of methacholine causing a 20% fall in FEV1; ppb, parts 
per billion.
Table 2 Continued 
In non-eosinophilic asthmatics, initiating (n=9) or 
increasing (n=13) ICS was associated with a worsening in 
ACQ (see table 6 for the effect on each question score) 
despite an increased usage of LABA, and overall no 
change in sputum and blood cells, except for a selective 
reduction in absolute blood basophils (table 5). When 
excluding patients with an initiation of LABA from the 
analysis, the effect on ACQ (1.7±1.0 to 2.3±1.2) and blood 
basophils (43 (35–78) to 31 (23–47)/µL) was still statisti-
cally significant (P<0.05).
Overall, the effect of an initiation/increased dose of 
ICS on asthma control, quality of life, exacerbation rate 
and FEV1 was statistically different between eosinophilic 
and non-eosinophilic asthmatics (figure 1).
effect of a cessation/decreased dose of Ics between two 
visits according to the baseline eosinophilic phenotype
In patients with eosinophilia, withdrawing (n=5) or 
decreasing (n=17) the dose of ICS resulted in a wors-
ening of asthma quality of life, together with an increase 
in sputum total cell count and sputum lymphocytes 
(table 7).
In non-eosinophilic asthmatics, withdrawing (n=13) or 
decreasing (n=25) the dose of ICS was associated with an 
improvement in asthma control and asthma quality of 
life as well as a reduction in the rate of severe exacerba-
tions, despite a decreased usage of LABA (table 7). They 
also showed an increased number of sputum and blood 
eosinophils and a decreased number of sputum macro-
phages and blood neutrophils (table 7). When excluding 
patients with a cessation of LABA from the analysis, there 
was still a statistically significant effect (P<0.05) on ACQ 
(1.8±1.1 to 1.4±1.0), mini-AQLQ (4.6±1.3 to 5.1±1.3), 
severe exacerbation number (1.1±0.5 to 0.4±0.3), sputum 
eosinophils (9 (0–18) to 42 (9–128) × 103/g and 0.4 
(0.0–1.8) to 2.8 (0.8–12.6)%), sputum macrophages (410 
(148–933) to 219 (120–412) × 103/g), blood eosinophils 
(188 (91–306) to 258 (148–453)/µL) and blood neutro-
phils (4816 (3414–5774) to 3785 (2811–5419)/µL).
Overall, the effect of a cessation/decreased dose of ICS 
on asthma control and asthma quality of life was statisti-
cally different between eosinophilic and non-eosinophilic 
asthmatics (figure 2).
DIscussIOn
To the best of our knowledge, our data are the first to 
provide evidence of effectiveness of ICS on airway and 
blood inflammation in real life. Initiating or increasing 
ICS in asthmatics sharply reduces sputum eosinophils 
and to a lesser extent blood eosinophils. Our data also 
show that effectiveness of ICS in reducing symptoms, 
improving quality of life and lung function and decreasing 
exacerbations is essentially observed in the eosinophilic 
asthma phenotype. On the other hand, our data suggest 
that stepping-down ICS in non-eosinophilic asthma may 
actually improve symptoms and quality of life and even 
reduce the exacerbation rate.
We provide here convincing evidence that ICS are 
powerful drugs to reduce airway eosinophilic inflam-
mation in clinical practice. As previously shown,6 11 we 
found that initiating/increasing the dose of ICS resulted 
in a greater decrease in sputum than in blood eosino-
phils. Whether this effect on blood eosinophils reflects a 
systemic action of ICS (by absorption through the lungs 
and gastrointestinal tract)25 or is a consequence of the 
local inhibition of IL-5 production/release26 remains to 
be elucidated. Whichever the reason, our results clearly 
show the preferential effect of ICS on the airway compart-
ment. As opposed to what was observed after initiating/
increasing the dose, a cessation/reduction in the dose of 
ICS resulted in an increase in sputum eosinophils, which 
is consistent with previous studies.8 9 At the systemic level, 
we noticed a significant reduction in the amount of circu-
lating blood neutrophils when decreasing the dose of ICS, 
maybe explained by the inhibitory effect of corticoste-
roids on neutrophil adhesion to endothelial cells.27 The 
lack of change in absolute sputum and circulating cells 
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Table 3 Comparison of clinical, treatment, sputum and blood characteristics before and after a cessation/decreased dose of 
ICS
Patients before 
a cessation/
decreased dose of ICS 
(N=60)
Patients after a 
cessation/decreased dose 
of ICS (N=60) P value
ACQ 2.0±1.3 1.8±1.2 0.19
Mini-AQLQ 4.3±1.5 4.6±1.5 0.066
Number of severe exacerbations in the previous year* 0.7±0.3† 0.2±0.1† 0.009
Prebronchodilator FEV1, % predicted 79.0±17.8 78.0±20.0 0.54
PC20M, mg/mL 16.00 (4.17->16)‡ 3.68 (1.52->16)‡ 0.069
ICS dose, beclomethasone equivalents 1600 (900–2100) 450 (0–1100) –
LABA, n (%) 50 (83) 42 (70) 0.057
LTRA, n (%) 18 (30) 16 (27) 0.63
Theophylline, n (%) 1 (2) 1 (2) 1.0
Antihistamine, n (%) 11 (18) 16 (27) 0.13
FENO, ppb 18 (12–48)§ 23 (13–47)§ 0.63
Sputum total non-squamous cell count, × 106/g 1.18 (0.53–3.51) 1.21 (0.65–2.67) 0.99
Sputum viability, % 70 (63–81) 68 (58–80) 0.54
Sputum squamous cells, % 16 (4–29) 14 (3–28) 0.52
Sputum eosinophils
  × 103/g 14 (1–120) 44 (5–239) 0.008
  % of non-squamous cells 1.9 (0.2–6.9) 2.8 (0.7–15.5) 0.016
Sputum neutrophils
  × 103/g 535 (146–1770) 854 (242–1469) 0.64
  % of non-squamous cells 48.9 (25.4–77.8) 61.0 (36.6–78.6) 0.13
Sputum macrophages
  × 103/g 353 (115–744) 247 (113–696) 0.39
  % of non-squamous cells 28.6 (11.2–54.9) 19.0 (11.3–34.7) 0.006
Sputum lymphocytes
  × 103/g 11 (2–50) 13 (6–56) 0.09
  % of non-squamous cells 1.2 (0.4–2.1) 1.4 (0.6–2.8) 0.19
Sputum epithelial cells
  × 103/g 53 (7–141) 49 (16–127) 0.91
  % of non-squamous cells 3.5 (1.0–9.9) 4.9 (1.6–8.9) 0.53
Blood leucocytes, × 109/L 7.68 (6.54–9.47) 7.42 (6.25–9.09) 0.21
Blood eosinophils
  /µL 207 (119–362) 246 (138–449) 0.08
  % 2.6 (1.8–4.5) 3.5 (1.8–5.4) 0.029
Blood neutrophils
  /µL 4476 (3530–5506) 3890 (3157–5438) 0.016
  % 58.8 (53.3–63.7) 54.3 (49.6–61.9) 0.023
Blood monocytes
  /µL 482 (387–629) 520 (430–637) 0.27
  % 6.4 (5.1–7.5) 7.5 (5.4–9.2) 0.046
Blood lymphocytes
  /µL 2260 (1749–2612) 2382 (1955–2945) 0.27
  % 28.9 (25.9–34.1) 33.0 (26.8–37.9) 0.022
Continued
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Patients before 
a cessation/
decreased dose of ICS 
(N=60)
Patients after a 
cessation/decreased dose 
of ICS (N=60) P value
Blood basophils
  /µL 38 (23–51) 38 (25–42) 0.17
  % 0.4 (0.4–0.7) 0.5 (0.3–0.6) 0.46
CRP, mg/L 2.9 (1.0–6.4)¶ 2.0 (0.7–5.4)¶ 0.14
Fibrinogen, g/L 3.5 (3.1–4.1)** 3.5 (3.0–3.7)** 0.22
*Data are presented as mean±SEM.
Data available for both visits in: †19, ‡16, §50, ¶32 and **28 patients.
ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; CRP, C reactive protein; FENO, fractional 
exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid; LABA, long-acting β2 agonist; LTRA, 
leukotriene receptor antagonist; PC20M, provocative concentration of methacholine causing a 20% fall in FEV1; ppb, parts 
per billion.
Table 3 Continued 
in the group of patients not receiving ICS or keeping the 
same dose of ICS between two visits (the control group) 
further supports the role of ICS in the changes found in 
the two preceding groups.
It is worth noting that neither the increase nor the 
decrease of ICS had an impact on markers of systemic 
inflammation like CRP or fibrinogen. This contrasts what 
has been shown in some28 29 but not all30 studies in which 
ICS were suggested to reduce the CRP levels in patients 
with chronic obstructive pulmonary disease (COPD). This 
might be explained by the fact that CRP levels are higher 
in patients with COPD as compared with asthmatics, 
thereby leaving room for a decrease with a drug interven-
tion. In patients with asthma, Takemura et al found that 
corticosteroid-naive, but not corticosteroid-treated asth-
matics had higher CRP levels than control subjects,31 but 
evidence from longitudinal studies is lacking.
A strength of our study is that our data further high-
light the importance of baseline eosinophilic pheno-
type in the response to ICS.10 14 Initiating or increasing 
the dose of ICS essentially provides clinical benefit in 
patients with baseline sputum eosinophils≥3%. In this 
group of patients, we observed a clear improvement in 
asthma control, asthma quality of life, baseline airway 
calibre as well as a reduction in bronchial hyper-respon-
siveness. Furthermore, there was also a marked reduction 
in the number of severe exacerbations recorded in the 
year prior to the visit. The average improvement in ACQ 
and mini-AQLQ reached at least 0.5, which is the indi-
vidual minimal important difference accepted for these 
questionnaires.20 32 Likewise, the improvement in bron-
chial hyper-responsiveness was above one doubling dilu-
tion, which is generally considered as clinically relevant.21 
The mean annual rate of severe exacerbations fell from 
0.8 to 0.1 per patient, yielding an 88% reduction. These 
results are consistent with previous studies showing that 
adjusting treatment with ICS to normalise the sputum 
eosinophil count resulted in a decrease in severe asthma 
exacerbations33 34 and with the fact that asthma control 
fluctuates with sputum eosinophils over time.23 We believe 
that sputum eosinophils are both a predictor of response 
to ICS and a therapeutic target of ICS.35 Contrasting with 
the clear effects observed in eosinophilic asthmatics, 
patients with a sputum eosinophil count less than 3% 
at baseline did not show any clinical benefit of an initi-
ation or an increase in the dose of ICS, and there was 
even a hint for a symptomatic deterioration of patients as 
there was a significant increase in ACQ between the two 
visits (accounted for by a raised frequency of nocturnal 
awakening due to asthma and an increased reliever use). 
This would suggest that it is useless to decide for a rise in 
ICS dosage in uncontrolled non-eosinophilic asthmatics. 
Therefore, these results emphasise the importance to 
assess the level of airway eosinophilic inflammation in 
clinical practice before treating patients with ICS, in 
order to reduce as much as possible inappropriate treat-
ment with corticosteroids.36 37
Our study also demonstrates that decreasing the dose 
of ICS in non-eosinophilic asthmatics may actually result 
in an improvement in asthma control and quality of life, 
maybe partly linked to the reduction of local side effects of 
ICS, like cough, pharyngitis or dysphonia.38 Surprisingly, 
there was also a reduction in exacerbation rate, although 
this should be taken with caution because of the limited 
number of subjects in whom the parameter was assessed 
(n=10). These results are consistent with the finding of 
Green et al showing in a subgroup analysis that it was 
possible to reduce the dose of ICS in non-eosinophilic 
asthmatics without any deterioration in asthma control.33 
In eosinophilic asthmatics, a reduction of ICS did not 
result in a dramatic rise in eosinophilic inflammation. 
Similarly, apart from a mild deterioration in quality of 
life, there was no impact of the ICS reduction on asthma 
control, baseline airway calibre and exacerbation rate. 
This might be explained by the fact that most patients 
in whom ICS were stepped down had a high dosage at 
baseline and were kept on a low-to-medium dose of ICS 
after the reduction, at which most of the benefits occur.39
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Table 4 Comparison of clinical, treatment, sputum and blood characteristics between two visits with no ICS or a stable dose 
of ICS
Patients with no ICS or a stable dose of 
ICS, visit 1 (N=63)
Patients with no ICS or a stable dose of 
ICS, visit 2 (N=63) P value
ACQ 1.7±1.1 1.7±1.2 0.91
Mini-AQLQ 4.7±1.3 4.8±1.5 0.42
Number of severe exacerbations in the previous year* 0.8±0.3† 0.7±0.3† 0.52
Prebronchodilator FEV1, % predicted 87.1±18.9 87.4±19.9 0.85
PC20M, mg/mL 2.62 (0.60–14.97)‡ 2.99 (0.20->16)‡ 0.94
ICS dose, beclomethasone equivalents 800 (0–2000) 800 (0–2000) –
LABA, n (%) 42 (67) 44 (70) 0.69
LTRA, n (%) 14 (22) 15 (24) 1.0
Theophylline, n (%) 2 (3) 2 (3) 1.0
Antihistamine, n (%) 13 (21) 11 (17) 0.75
FENO, ppb 26 (14-48)§ 24 (12-48)§ 0.93
Sputum total non-squamous cell count, × 106/g 1.10 (0.45–2.40) 1.29 (0.43–2.53) 0.64
  Sputum viability, % 66 (47–80) 63 (49–80) 0.90
  Sputum squamous cells, % 15 (7–28) 16 (3–32) 0.86
Sputum eosinophils
  × 103/g 18 (2–168) 36 (3–149) 0.78
  % of non-squamous cells 1.6 (0.2–17.8) 1.8 (0.5–13.0) 0.53
Sputum neutrophils
  × 103/g 468 (144–1954) 497 (214–1270) 0.99
  % of non-squamous cells 45.0 (26.6–76.0) 61.0 (33.6–81.0) 0.041
Sputum macrophages
  × 103/g 222 (122–663) 237 (74–516) 0.09
  % of non-squamous cells 23.2 (13.4–46.6) 20.0 (9.8–34.0) 0.011
Sputum lymphocytes
  × 103/g 11 (2–35) 10 (1–34) 0.52
  % of non-squamous cells 1.2 (0.4–2.8) 0.8 (0.3–1.8) 0.17
Sputum epithelial cells
  × 103/g 50 (16–95) 36 (10–96) 0.83
  % of non-squamous cells 5.2 (1.6–9.8) 2.6 (1.0–9.5) 0.52
Blood leucocytes, × 109/L 7.82 (6.70–8.94) 8.03 (6.52–9.15) 0.62
Blood eosinophils
  /µL 198 (132–342) 248 (120–471) 0.10
  % 2.7 (1.6–4.3) 2.9 (1.6–6.8) 0.09
Blood neutrophils
  /µL 4221 (3473–5177) 4380 (3540–5395) 0.80
  % 55.5 (50.4–61.0) 55.9 (49.5–63.6) 0.96
Blood monocytes
  /µL 568 (413–672) 543 (402–702) 0.49
  % 6.9 (5.1–8.9) 6.9 (5.3–8.3) 0.91
Blood lymphocytes
  /µL 2520 (2091–2900) 2404 (1932–2873) 0.28
  % 31.4 (26.9–35.7) 30.1 (24.2–36.1) 0.27
Blood basophils
  /µL 38 (23–53) 38 (23–53) 0.69
  % 0.5 (0.3–0.6) 0.5 (0.3–0.7) 0.91
CRP, mg/L 1.5 (0.7–3.8)¶ 2.4 (0.8–5.3)¶ 0.33
Fibrinogen, g/L 3.6 (3.1–3.8)** 3.7 (3.3–4.4)** 0.10
*Data are presented as mean±SEM.
Data available for both visits in: †26, ‡24, §54, ¶41 and **36 patients.
ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; CRP, C reactive protein; FENO, fractional exhaled nitric oxide; FEV1, forced expiratory 
volume in 1 s; ICS, inhaled corticosteroid; LABA, long-acting β2 agonist; LTRA, leukotriene receptor antagonist; PC20M, provocative concentration of methacholine causing a 
20% fall in FEV1; ppb, parts per billion.
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Table 6 Detailed analysis of the score for each ACQ question before and after an initiation/increased dose of ICS in non-
eosinophilic asthmatics
ACQ questions (score ranging from 0 to 6 for each 
question)19
Non-eosinophilic 
asthmatics before 
an initiation/
increased dose of ICS 
(n=22)
Non-eosinophilic 
asthmatics after 
an initiation/
increased dose of ICS 
(n=22) P value
1. Frequency of nocturnal awakening due to asthma 0.5±1.1 1.3±1.6 0.039
2. Severity of asthma symptoms when waking 1.4±1.3 1.7±1.3 0.34
3. Limitation in activities 1.6±1.4 1.9±1.6 0.16
4. Frequency of shortness of breath 2.1±1.4 2.3±1.8 0.51
5. Frequency of wheeze 1.5±1.3 2.1±1.6 0.13
6. Frequency of short-acting β2 agonist use 0.6±0.8 1.3±1.5 0.015
7. Prebronchodilator FEV1 (% predicted) 1.9±1.8 2.3±2.2 0.27
ACQ, Asthma Control Questionnaire; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid.
Figure 1 Comparison of the effect of an initiation/increased dose of inhaled corticosteroid (ICS) on (A) Asthma Control 
Questionnaire (ACQ), (B) mini-Asthma Quality of Life Questionnaire (mini-AQLQ), (C) severe exacerbation rate and (D) forced 
expiratory volume in 1 s (FEV1) in eosinophilic and non-eosinophilic asthmatics. The red and blue horizontal lines represent the 
mean values in eosinophilic and non-eosinophilic asthmatics, respectively. EA, eosinophilic asthma; NEA, non-eosinophilic 
asthma.
Determining the eosinophilic or non-eosinophilic 
phenotype is not widely available in clinical practice 
because the technique of induced sputum is tech-
nically demanding and time-consuming. While its 
implementation may be possible in secondary care 
centres, we acknowledge that it would be impracticable 
in primary care centres. However, when the technique 
of induced sputum is not available, several user-friendly 
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Figure 2 Comparison of the effect of a cessation/decreased dose of inhaled corticosteroid (ICS) on (A) Asthma Control 
Questionnaire (ACQ), (B) mini-Asthma Quality of Life Questionnaire (mini-AQLQ), (C) severe exacerbation rate and (D) forced 
expiratory volume in 1 s (FEV1) in eosinophilic and non-eosinophilic asthmatics. The red and blue horizontal lines represent the 
mean values in eosinophilic and non-eosinophilic asthmatics, respectively. EA, eosinophilic asthma; NEA, non-eosinophilic 
asthma.
surrogate markers might be used to predict the presence 
or absence of sputum eosinophilia, like FENO, blood 
eosinophils and total serum IgE.40 Moreover, it would be 
worth investigating in large real-life studies the ability of 
those biomarkers to predict response to ICS by compar-
ison with sputum eosinophils.
Being retrospective, our study has several limitations. 
Due to the variation in the delay between both visits and 
to the unknown adherence to treatment, the cumulative 
dose of ICS received by the patients before the investi-
gation remains uncertain. A second limitation of our 
study is the fact that ICS were not the only drugs to be 
changed between both visits, as in the large majority of 
patients, ICS were combined with LABA which may also 
impact clinical outcomes. However, the fact that most 
results remained statistically significant when patients 
with variations in LABA use were excluded from the 
analysis enhances confidence in the findings. A third 
limitation of our study is that the reason why the dose 
of ICS was changed between both visits may be plural: 
it can either be related to a recommended strategic 
treatment choice by the chest physician or the general 
practitioner, or linked to a loose adherence of patients 
to their treatment plan. Finally, we did not perform 
any formal sample size calculation in our study and we 
therefore acknowledge that the statistical power may be 
insufficient for several comparisons in our results.
To conclude, our results confirm the effectiveness of 
ICS on eosinophilic inflammation in real life and demon-
strate the clinical benefit of initiating or raising the dose 
of ICS in eosinophilic asthma, but cast doubt on the clin-
ical utility of stepping-up ICS in non-eosinophilic asthma. 
Our data also suggest that high dose of ICS can be safely 
stepped down in non-eosinophilic asthmatics. Overall, we 
believe that the benefits of ICS in non-eosinophilic asth-
matics should be clarified in long-term prospective trials.
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